Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination of Cobimetinib and Atezolizumab at ASCO 2016 Annual Meeting
Exelixis and Its Partner Ipsen Announce Phase 3 Trial Results of CABOMETYX™ (Cabozantinib) Tablets Demonstrating Significant Overall Survival Benefit for Previously Treated Patients with Advanced Renal Cell Carcinoma Presented at ASCO
Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX™ (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO
Exelixis's stock surges after positive results from trial of kidney cancer treatment
Global Pre-harvest Equipment Market Report 2016-2022 - Analysis, Technologies & Forecasts - Key Vendors: AGCO, Toro Company, DEERE & Company - Research and Markets
The lack of early success in its lead drug's cancer trial scares the market, but we see a buying opportunity.
Global Bladder Cancer Pipeline Report 2016 - Review of 94 Companies & Drug Profiles - Research and Markets
Lack of competitive advantages may mean these companies aren't the bargains they seem to be.
We see opportunity as fleeing investors trigger an irrational sell-off.
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.